Chattem completes acquisition
This article was originally published in The Rose Sheet
Executive Summary
Chattem announces Jan. 2 it has closed its agreement to purchase, for $410 mil. in cash, the U.S. rights to five brands divested in connection with Johnson & Johnson's acquisition of Pfizer's Consumer Healthcare business, including anti-cavity mouthwash brand ACT (1"The Rose Sheet" Oct. 9, 2006, In Brief). "We are very excited to add these leading brands to the company's existing portfolio of quality products," Chattem CEO and Chairman Zan Guerry says. Chattem will replace Fidelity Bankshares in Standard & Poor's SmallCap 600 index after the close of trading Jan. 5...